The determination of genomic aberrations in ESR1, mitogen-activated protein kinase (MAPK), Retinoblastoma gene 1 (RB1), Thr790Met (T790M), Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and proto-oncogene B-Raf (BRAF) genes that appear after chemotherapy treatments in breast cancer with aromatase inhibitors [20] or CDK4/6 inhibitors [21], lung cancer with osimertinib [22], colon cancer with cetuximab [23] and melanoma with BRAF inhibitors [24] may provide a better strategy to delay drug resistance. This evidence concerns the gene CYP19A1 and malignant colon neoplasm.